Audit, tax and consulting firm RSM has established a new technology and management consulting hub in the North West.
Operating from the company’s offices in Manchester city centre, the hub represents the latest move in a drive to expand RSM’s core services nationally, particularly in IT and digital strategy, cloud ERP and management consulting services.
Dstl is working in partnership with Government Communications Headquarters (GCHQ) and the Alan Turing Institute – the national Institute for data science – on a number of defence challenges that exploit the power of data science.
NHS England has awarded £8.7m to 10 companies that are developing new technologies aimed at 'future-proofing' general practice.
Some of the companies are developing technology to support self-care
The funding has been awarded via Small Business Research Initiative (SBRI) Healthcare, an NHS England scheme that works with England’s 15 Academic Health Science Networks to identify new technologies developed by small businesses and start-ups that could help improve patient care and increase efficiency.
Apple CEO Tim Cook talked up the company's ambitions in the health-care sector on Tuesday, hinting that it will move beyond wellness apps and devices, like its step-tracking Apple Watch.
Cook acknowledged at the company's annual shareholders meeting in Cupertino, California, that the health-care sector, which is notoriously complex, doesn't always encourage new players to innovate. But he reassured shareholders that he views Apple as having a "great position," in the sector, by taking a more consumer-friendly approach.
China is calling for deeper cooperation on the internet of things among countries around the world, and to jointly launch a global demonstration platform for the IoT, said He Xuming, executive chairman of the World Internet of Things Convention.
Recently, the city of Wuhan announced that they will be opening a police station run solely by artificial intelligence (AI) – no employees need to apply. Although the station would be limited to vehicle and driver related administrative work, the government anticipates increasing AI use in many other areas of governance.
It has been a momentous month for healthcare agreements between the UK and China, with the announcement of numerous collaborations by UK companies in healthcare and life sciences with their Chinese partners
For over 30 years, Silicon Valley has been known as the world's center for digital innovation, but that perception is becoming as fresh as a flip phone. China is determined to become the world leader in the IoT, and just launched the second half of a ten-year, $US60 billion plan to cultivate domestic innovation in this space. Global IoT players with an eye toward success are thinking less about competition and more about cooperation.
Even though the healthcare industry has been slower to adopt Internet of Things technologies than other industries, the Internet of Medical Things (IoMT) is poised to transform how we keep people safe and healthy especially as the demand for solutions to lower healthcare costs increase in the coming years. The IoMT can help monitor, inform and notify not only care-givers, but provide healthcare providers with actual data to identify issues before they become critical or to allow for earlier invention
Equiteq, the knowledge economy M&A specialist, is pleased to announce that it has advised Insight Strategy Advisors (ISA), a premier life sciences strategy consultancy, on its sale to Precision Value & Health, a part of Precision Medicine Group. ISA will become part of Precision Xtract, the global market access consultancy within Precision Value & Health.
NEHI puts a price on patients not adhering to treatment. It’s $290 Billion worth of a new problem for the pharmaceuticals industry – getting beyond the pill to influence the behaviours or patients and thereby influence the outcomes on which their reimbursements, and ultimately profitability, depends. Investment in patient access and adherence technology and programs is set to increase exponentially over the next five years, but if this investment is going to pay off, the data strategy to understand what patients are doing (or not doing) and why needs to be clear.
Finally it’s a reality that EU Pricing is contagious – and the US market is already showing some early symptoms including cold sweats, bouts of litigiousness, and the kind of migraine that can only be brought on by Risk Sharing Agreements.
The Cancer Drugs Fund achieved many of its aims. It transformed access to breakthrough oncology drugs in the UK, and brought the NHS closer to the levels of access seen elsewhere in Europe. If someone had pointed to the elephant in the room, it might still be here in it's former shape.
The value assessment frameworks introduced into the US in 2015 take a very static view of value, or more precisely value demonstration. By not considering Real-world evidence alongside trials data these new frameworks risk pushing the industry into a stalemate – increasingly complex commercial models, which are not then supported and enabled by a value assessment process which recognizes sub-populations of patients. Put simply, next-generation sequencing in genomics has pushed the envelope while definitions of value are still preoccupied with franking the mail.